Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
28 févr. 2023 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively – – ARCALYST full-year 2023 net product revenue expected to be $190 - $205...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
27 févr. 2023 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023,...
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
09 janv. 2023 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) – – 2 of 3 cohorts enrolled in KPL-404 Phase 2 trial in...
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday,...
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
30 nov. 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America...
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
23 nov. 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual...
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
01 nov. 2022 08h00 HE
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) Q3 2022 net revenue of $33.4 million –– RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard...
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
31 oct. 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022,...
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
12 sept. 2022 08h30 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate...
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
03 août 2022 16h01 HE
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow...